RADX (Radiopharm Theranostics) Other Financing: $-4.20 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RADX Radiopharm Theranostics Ltd RADX
33 GF Score
Price $2.08
GF Value $2.34
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Radiopharm Theranostics Other Financing?

Radiopharm Theranostics RADX -1.42% 33 Other Financing is $-4.20 Mil as of Jun. 2025. GuruFocus rates RADX with a GF Score™ of 33/100 and a GF Value™ of $2.34 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Radiopharm Theranostics's Other Financing for the six months ended in Jun. 2025 was $0.45 Mil.

Radiopharm Theranostics's Other Financing for the trailing twelve months (TTM) ended in Jun. 2025 was $-4.20 Mil.

Radiopharm Theranostics Other Financing Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Other Financing Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25 Jun26
Other Financing
-3.40 -0.57 -1.10 -4.33 -1.41

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only -0.09 -1.46 -4.65 0.45 0.00
RADX
33GF Score
Radiopharm Theranostics Ltd RADX
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Radiopharm Theranostics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-4.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-4.20 Mil mean?
Radiopharm Theranostics (RADX) has a Other Financing of $-4.20 Mil as of Jun. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Radiopharm Theranostics and its competitors.
Is Radiopharm Theranostics' Other Financing too high?
Radiopharm Theranostics' current Other Financing is $-4.20 Mil. Overall, Radiopharm Theranostics has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Radiopharm Theranostics' Other Financing compare to VRTX and REGN?
Radiopharm Theranostics' Other Financing of $-4.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Other Financing is $-4.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Based on GuruFocus' analysis, Radiopharm Theranostics (RADX) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.34, compared to a current price of $2.08 — trading 11.1% below its estimated fair value. The current Other Financing is $-4.20 Mil. Radiopharm Theranostics' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Radiopharm Theranostics (RADX), the current Other Financing is $-4.20 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Radiopharm Theranostics (RADX) Overvalued in 2026?

Based on GuruFocus' analysis, Radiopharm Theranostics stock appears to be undervalued. The current stock price of $2.08 is trading 11.1% below its estimated GF Value™ of $2.34. GuruFocus considers Radiopharm Theranostics to be Modestly Undervalued.

Key valuation signals for RADX:

  • Other Financing: $-4.20 Mil
  • GF Value™: $2.34 vs. price of $2.08 (11.1% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the RADX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Radiopharm Theranostics Business Description

Other Exchanges RAD:Australia
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
33GF Score

Get the complete analysis for RADX

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price
$2.34
GF Value